Stock offerings
Ocugen Closes Registered Direct Offering, Secures $50 Million in Funding
Ocugen, a pioneering biotechnology leader in gene therapies for blindness diseases, has successfully closed its registered direct offering, securing $50 million in funding. The company announced the closing of its previously announced offering to Janus Henderson Investors, which consisted of 20 million shares of common stock and warrants to purchase